Association between ALT level and the rate of cardio/cerebrovascular events in HIV-positive individuals: The D: A: D study

Journal of Acquired Immune Deficiency Syndromes

Volumn 63, Issue 4, 2013, Pages 456-463

  Sabin, Caroline A ^a   Ryom, Lene ^b,c   Kovari, Helen ^d   Kirk, Ole ^b,c   De Wit, Stephane ^e   Law, Matthew ^f   Reiss, Peter ^g   Dabis, Francois ^h   Pradier, Christian ⁱ   El Sadr, Wafaa ^j   Monforte, Antonella D'Arminio ^k   Kamara, David ^a   Phillips, Andrew N ^a   Lundgren, Jens D ^b,c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

^e SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^f UNIVERSITY OF NEW SOUTH WALES   (Australia)

^g ACADEMIC MEDICAL CENTER   (Netherlands)

^h UNIVERSITÉ DE BORDEAUX   (France)

ⁱ UNIVERSITY HOSPITAL OF NICE   (France)

^j Howard Hughes Medical Institute   (United States)

^k UNIVERSITY OF MILAN   (Italy)

more..

Author keywords

Alanine aminotransferase; Cardiovascular disease; Coronary heart disease; Myocardial infarction; Stroke

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIRETROVIRUS AGENT;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG EXPOSURE; DRUG USE; FEMALE; HEART INFARCTION; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PRIORITY JOURNAL;

ADULT; ALANINE TRANSAMINASE; CONFIDENCE INTERVALS; CORONARY DISEASE; FEMALE; HEPATITIS C; HIV SEROPOSITIVITY; HUMANS; LIVER DISEASES; MALE; MYOCARDIAL INFARCTION; POISSON DISTRIBUTION; REGRESSION ANALYSIS; RISK FACTORS; STROKE; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 84880218629     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318291cd29     Document Type: Article

References (23)

1. Miyake T, Kumagi T, Hirooka M, et al. Metabolic markers and ALT cutoff level for diagnosing non-alcoholic fatty liver disease:A community- based cross-ectional study. J Gastroenterol. 2012;47:696-703.
2. Bansi L, Gazzard B, Post F, et al. Biomarkers measured to monitor safety in people on ART and risk of mortality. J Acquir Immune Defic Syndr. 2012;60:51-58.
3. Ruhl CE, Everhart JE. Elevated serum alanine aminotransferase and gamma-glutamyltransferase and mortality in the United States population. Gastroenterology. 2009;136:477-485.
4. Goessling W, Massaro JM, Vasan RS, et al. Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease. Gastroenterology. 2008;135:1935-1944.
5. Price JC, Seaberg EC, Badri S, et al. HIV monoinfection is associated with increased aspartate aminotransferase-to-platelet ratio index, a surrogate marker for hepatic fibrosis. J Infect Dis. 2012;205:1005-1013.
6. Ford I, Mooijaart SP, Lloyd S, et al. The inverse relationship between alanine aminotransferase in the normal range and adverse cardiovascular and non-cardiovascular outcomes. Int J Epidemiol. 2011;40:1530-1538.
7. Bansi L, Turner J, Gilson R, et al. Is 1 alanine transaminase .200 IU enough to define an alanine transaminase flare in HIV-infected populations? A new definition derived from a large cohort study. J Acquir Immune Defic Syndr. 2009;52:391-396.
8. Vogel M, Rockstroh JK. Hepatotoxicity and liver disease in the context of HIV therapy. Curr Opin HIV AIDS. 2007;2:306-313.
9. Wit F, Weverling G, Weel J, et al. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis. 2002;186:23-31.
10. Kovari H, Ledergerber B, Battegay M, et al. Incidence and risk factors for chronic elevation of alanine aminotransferase levels in HIV-infected persons without hepatitis B or C virus co-infection. Clin Infect Dis. 2010; 50:502-511.
11. Triant VA. HIV infection and coronary heart disease: An intersection of epidemics. J Infect Dis. 2012;205(suppl 3):S355-361.
12. Baker JV, Lundgren JD. Cardiovascular implications from untreated human immunodeficiency virus infection. Eur Heart J. 2011;32:945-951.
13. Worm SW, Sabin C, Weber R, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes:The data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis. 2010:201:318-330.
14. Friis-Moller N, Weber R, Reiss P, et al. Cardiovascular disease risk factors in HIV patients: Association with antiretroviral therapy. Results from the DAD study. AIDS. 2003;17:1179-1193.
15. Kowalska JD, Friis-Moller N, Kirk O, et al. The Coding Causes of Death in HIV (CoDe) Project:initial results and evaluation of methodology. Epidemiology. 2011;22:516-523.
16. Weber R, Smith C, D:A:D Study Group. Trends over time in underlying causes of death in the D:A:D Study from 1999-2011. Abstract THAB0304. XIX International AIDS Conference. Washington, DC; 2012.
17. Alberton M, Wu P, Druyts E, et al. Adverse events associated with individual statin treatments for cardiovascular disease: An indirect comparison meta-analysis. QJM. 2012;105:145-157.
18. Schindhelm RK, Dekker JM, Nijpels G, et al. Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study. Atherosclerosis. 2007;191:391-396.
19. The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group. HBV or HCV coinfections and risk of myocardial infarction in HIV-infected individuals:The D:A:D Cohort Study. Antivir Ther. 2010;15:1077-1086.
20. Kovari H, Weber R. Influence of ART on liver disease. Curr Opin HIV AIDS. 2011;6:272-277.
21. Podzamcszer D, Andrade-Villanueva J, Clotet B, et al. Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-naïve HIV-1- infected patients (the ARTEN study). HIV Med. 2011;12:374-382.
22. Zyriax BC, Lau K, Klahn T, et al. Association between alcohol consumption and carotid intima-media thickness in a healthy population:data of the STRATEGY study (Stress, Atherosclerosis and ECG Study). Eur J Clin Nutr. 2010;64:1199-1206.
23. Tsai J, Ford ES, Li C, et al. Past and current alcohol consumption patterns and elevations in serum hepatic enzymes among US adults. Addict Behav. 2012;37:78-84. Prevención del SIDA en Espanã